KPV
Anti-Inflammatory Tripeptide | Alpha-MSH Fragment
Overview
KPV is a potent anti-inflammatory tripeptide derived from the C-terminal of alpha-MSH. It exhibits remarkable anti-inflammatory and antimicrobial properties without the pigmentation effects of full α-MSH, making it ideal for inflammation management.
Key benefits
- Systemic anti-inflammatory effects
- No pigmentation/tanning effects
- Immune modulation without immunosuppression
- Potential for autoimmune conditions
- Gut health support
- Multiple delivery routes available
Mechanism of action
Enters cells and inhibits inflammatory pathways at the nuclear level, particularly NF-κB signaling. Reduces pro-inflammatory cytokines (TNF-α, IL-6) without causing immunosuppression like steroids.
Molecular data
- Type
- Tripeptide
- Half-life
- 1-2 hours
Indications
What the research community uses this compound for, with self-reported effectiveness.
Inflammation
Gut Health
Skin Health
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 200-300mcg | Once daily | — |
| — | 250mcg | Twice daily | — |
| — | 500mcg | Once daily | — |
| — | 500mcg | 2x daily for 1 week, then reduce | — |
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 200-500mcg | 2-3x daily | — |
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 0.1-0.5% cream/gel | 2-3x daily | — |
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 100-300mcg | 2-3x daily (1-2 sprays per nostril) | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Minimal to no side effects reported
- Does not cause immunosuppression like steroids
- No melanin production/tanning effects
- May temporarily reduce inflammation-related symptoms
Contraindications
- Known peptide allergies
- Active severe infections (theoretical)
- Pregnancy or breastfeeding (limited data)
Monitoring
- Monitor for signs of infection (rare)
- Track inflammatory symptom improvement
- Generally well-tolerated at higher doses
References
Primary literature and clinical-trial data informing this entry.